Scholar Rock Holding Corp (SRRK)
Every FINRA and SEC series the site collects for Scholar Rock Holding Corp: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).
18.2M
Short interest
settlement 2026-08-14
19.8
Days to cover
+3.1% vs prior
63.5%
Short share of volume
2026-09-11
15,551
Fails to deliver
settlement 2026-08-14
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in SRRK is 18,218,515 shares, up 621,343 shares over the last month. Over the last 48 readings it ranged from 14,173,937 shares (15 July 2025) to 18,375,421 shares (30 June 2026). The latest reading sits at the top of that range. At the reported average volume of 919K shares a day that is 19.8 days to cover, a crowded short.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/srrk" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 18,218,515 | +3.1% | 919,253 | 19.82 |
| 2026-07-31 | 17,667,182 | +0.4% | 1,088,801 | 16.23 |
| 2026-07-15 | 17,597,172 | -4.2% | 1,089,596 | 16.15 |
| 2026-06-30 | 18,375,421 | +9.8% | 2,554,061 | 7.19 |
| 2026-06-15 | 16,731,033 | +1.8% | 1,035,621 | 16.16 |
| 2026-05-29 | 16,428,271 | +4.9% | 1,210,877 | 13.57 |
| 2026-05-15 | 15,662,038 | +5.1% | 1,314,747 | 11.91 |
| 2026-04-30 | 14,906,364 | +0.6% | 1,382,538 | 10.78 |
| 2026-04-15 | 14,813,843 | -5.9% | 1,543,208 | 9.60 |
| 2026-03-31 | 15,736,891 | +10.1% | 1,994,558 | 7.89 |
| 2026-03-13 | 14,294,013 | -1.5% | 1,620,294 | 8.82 |
| 2026-02-27 | 14,518,252 | -7.0% | 801,852 | 18.11 |
| 2026-02-13 | 15,619,362 | +0.6% | 934,297 | 16.72 |
| 2026-01-30 | 15,533,415 | -0.8% | 936,586 | 16.59 |
| 2026-01-15 | 15,666,804 | +6.3% | 1,153,820 | 13.58 |
| 2025-12-31 | 14,743,037 | -11.4% | 914,282 | 16.13 |
| 2025-12-15 | 16,646,564 | +4.4% | 1,644,162 | 10.12 |
| 2025-11-28 | 15,949,554 | -7.1% | 2,002,011 | 7.97 |
| 2025-11-14 | 17,166,122 | -4.1% | 2,042,098 | 8.41 |
| 2025-10-31 | 17,901,453 | +5.8% | 2,558,023 | 7.00 |
| 2025-10-15 | 16,920,104 | +3.0% | 3,513,013 | 4.82 |
| 2025-09-30 | 16,419,558 | +2.1% | 3,325,560 | 4.94 |
| 2025-09-15 | 16,075,866 | -4.5% | 1,810,032 | 8.88 |
| 2025-08-29 | 16,829,723 | +8.8% | 1,950,377 | 8.63 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of SRRK volume is 63.5%, up 5.2 points over the last five sessions. Over the last 52 readings it ranged from 25.4% (21 July 2026) to 79.5% (16 July 2026). The latest reading is 4.7 points above the 30-session average of 58.7%, on 389K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 247K | 389K | 63.5% | 0 |
| 2026-09-10 | 266K | 568K | 46.8% | 0 |
| 2026-09-09 | 421K | 913K | 46.1% | 154 |
| 2026-09-08 | 316K | 490K | 64.4% | 8,520 |
| 2026-09-04 | 107K | 199K | 53.7% | 0 |
| 2026-09-03 | 147K | 252K | 58.2% | 1,200 |
| 2026-09-02 | 247K | 420K | 58.7% | 5,397 |
| 2026-09-01 | 178K | 344K | 51.7% | 0 |
| 2026-08-31 | 119K | 329K | 36.1% | 0 |
| 2026-08-28 | 245K | 336K | 73.1% | 787 |
| 2026-08-27 | 191K | 285K | 66.9% | 824 |
| 2026-08-26 | 640K | 1.2M | 54.6% | 855 |
| 2026-08-25 | 239K | 508K | 47.1% | 813 |
| 2026-08-24 | 372K | 578K | 64.3% | 9,609 |
| 2026-08-21 | 301K | 563K | 53.5% | 0 |
| 2026-08-20 | 213K | 439K | 48.4% | 408 |
| 2026-08-19 | 246K | 412K | 59.7% | 0 |
| 2026-08-18 | 253K | 584K | 43.3% | 1,090 |
| 2026-08-17 | 146K | 205K | 71.4% | 315 |
| 2026-08-14 | 114K | 188K | 60.5% | 0 |
| 2026-08-13 | 319K | 407K | 78.5% | 1,371 |
| 2026-08-12 | 164K | 328K | 50.1% | 3,651 |
| 2026-08-11 | 244K | 340K | 71.8% | 300 |
| 2026-08-10 | 169K | 379K | 44.7% | 0 |
| 2026-08-07 | 342K | 440K | 77.7% | 7,000 |
| 2026-08-06 | 548K | 802K | 68.3% | 0 |
| 2026-08-05 | 277K | 389K | 71.3% | 0 |
| 2026-08-04 | 209K | 297K | 70.2% | 0 |
| 2026-08-03 | 114K | 336K | 34.0% | 0 |
| 2026-07-31 | 277K | 380K | 73.0% | 290 |
Fails to deliver
SEC, by settlement date. JSONAs of 14 August 2026, the fails-to-deliver balance in SRRK is 15,551 shares, up 15,550 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (10 August 2026) to 194,807 shares (9 December 2025). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-14 | 15,551 | $53.06 | $825K |
| 2026-08-10 | 1 | $52.92 | $53 |
| 2026-08-06 | 37 | $47.87 | $2K |
| 2026-08-04 | 75,223 | $45.85 | $3.4M |
| 2026-08-03 | 14,693 | $47.30 | $695K |
| 2026-07-27 | 865 | $47.67 | $41K |
| 2026-07-23 | 30 | $48.30 | $1K |
| 2026-06-30 | 5,570 | $54.96 | $306K |
| 2026-06-29 | 6,564 | $54.76 | $359K |
| 2026-06-25 | 3,097 | $52.33 | $162K |
| 2026-06-23 | 10,786 | $49.19 | $531K |
| 2026-06-18 | 56 | $46.95 | $3K |
| 2026-06-17 | 583 | $45.56 | $27K |
| 2026-06-08 | 20,415 | $44.30 | $904K |
| 2026-06-04 | 472 | $44.64 | $21K |
| 2026-04-24 | 338 | $47.48 | $16K |
| 2026-04-21 | 3,357 | $47.80 | $160K |
| 2026-04-20 | 357 | $49.96 | $18K |
| 2026-03-30 | 4,321 | $42.60 | $184K |
| 2026-03-27 | 268 | $44.21 | $12K |
| 2026-03-26 | 242 | $45.43 | $11K |
| 2026-03-23 | 4,292 | $44.64 | $192K |
| 2026-03-17 | 2,155 | $40.26 | $87K |
| 2026-03-03 | 20,081 | $43.48 | $873K |
| 2026-03-02 | 1,719 | $44.27 | $76K |
| 2026-02-23 | 81 | $48.00 | $4K |
| 2026-02-06 | 14,904 | $44.45 | $662K |
| 2026-02-04 | 3,370 | $47.95 | $162K |
| 2026-02-02 | 579 | $44.34 | $26K |
| 2026-01-29 | 187 | $43.13 | $8K |
Insider trades
SEC Form 4, newest first, 50 of 84 shown. JSONNo open-market insider trades were reported for SRRK in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: Reed Joshua on 2026-06-04.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Reed Joshua | n/a | Grant | 7K | $0.00 | $0 | 23K |
| 2026-06-04 | Peng Katie | n/a | Grant | 7K | $0.00 | $0 | 40K |
| 2026-06-04 | Gilman Michael | n/a | Grant | 7K | $0.00 | $0 | 62K |
| 2026-06-04 | FLIER JEFFREY S. | n/a | Grant | 7K | $0.00 | $0 | 31K |
| 2026-06-04 | Burow Kristina | n/a | Grant | 7K | $0.00 | $0 | 118K |
| 2026-06-04 | Brudnick Richard | n/a | Grant | 7K | $0.00 | $0 | 22K |
| 2026-06-04 | AKKARAJU SRINIVAS | n/a | Grant | 7K | $0.00 | $0 | 28K |
| 2026-04-23 | Burow Kristina | n/a | Option exercise | 18K | $8.36 | $150K | 111K |
| 2026-04-23 | Burow Kristina | n/a | Option exercise | 36K | $9.11 | $328K | 93K |
| 2026-04-23 | Burow Kristina | n/a | Option exercise | 28K | $4.75 | $133K | 57K |
| 2026-04-23 | Burow Kristina | n/a | Option exercise | 8K | $26.78 | $209K | 29K |
| 2026-04-16 | Woods Keith | Chief Operating Officer | Sell | 10K | $49.57 | $507K | 620K |
| 2026-04-16 | Vaishnaw Akshay | President of R&D | Sell | 12K | $49.57 | $607K | 631K |
| 2026-04-16 | Sinha Vikas | Chief Financial Officer | Sell | 10K | $49.57 | $516K | 620K |
| 2026-04-16 | Hallal David | Chief Executive Officer | Sell | 31K | $49.57 | $1.5M | 1.6M |
| 2026-02-23 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 200 | $48.48 | $10K | 98K |
| 2026-02-23 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 857 | $47.86 | $41K | 99K |
| 2026-02-23 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 7K | $46.94 | $349K | 100K |
| 2026-02-17 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 8K | $46.53 | $372K | 107K |
| 2026-02-17 | Parlavecchio Caryn | CHRO | Sell | 9K | $46.53 | $420K | 169K |
| 2026-02-17 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 4K | $46.53 | $193K | 126K |
| 2026-02-17 | Ho Junlin | GENERAL COUNSEL | Sell | 10K | $46.53 | $446K | 242K |
| 2026-02-09 | Vaishnaw Akshay | President of R&D | Grant | 47K | $0.00 | $0 | 643K |
| 2026-02-09 | Sinha Vikas | Chief Financial Officer | Grant | 47K | $0.00 | $0 | 630K |
| 2026-02-09 | Woods Keith | Chief Operating Officer | Grant | 47K | $0.00 | $0 | 630K |
| 2026-02-09 | Qatanani Mo | Chief Scientific Officer | Grant | 29K | $0.00 | $0 | 115K |
| 2026-02-09 | Parlavecchio Caryn | Chief Human Resources Officer | Grant | 29K | $0.00 | $0 | 178K |
| 2026-02-09 | Marantz Jing L. | Chief Medical Officer | Grant | 34K | $0.00 | $0 | 130K |
| 2026-02-09 | Ho Junlin | General Counsel | Grant | 37K | $0.00 | $0 | 251K |
| 2026-02-09 | Hallal David | Chief Executive Officer | Grant | 128K | $0.00 | $0 | 1.7M |
| 2026-01-22 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 13K | $46.85 | $599K | 86K |
| 2026-01-22 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 2K | $45.87 | $97K | 98K |
| 2026-01-16 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 8K | $44.48 | $374K | 101K |
| 2026-01-16 | Parlavecchio Caryn | CHRO | Sell | 7K | $44.48 | $294K | 149K |
| 2026-01-16 | Marantz Jing L. | CHIEF MEDICAL OFFICER | Sell | 6K | $44.48 | $258K | 96K |
| 2026-01-16 | Ho Junlin | GENERAL COUNSEL | Sell | 8K | $44.48 | $357K | 215K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Sell | 13K | $45.20 | $593K | 109K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Option exercise | 3K | $35.15 | $94K | 122K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Option exercise | 6K | $15.75 | $93K | 119K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Option exercise | 3K | $10.00 | $28K | 114K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Option exercise | 321 | $7.62 | $2K | 111K |
| 2026-01-14 | Qatanani Mo | CHIEF SCIENTIFIC OFFICER | Option exercise | 1K | $18.08 | $25K | 110K |
| 2026-01-13 | Sinha Vikas | Chief Financial Officer | Sell | 17K | $42.70 | $715K | 583K |
| 2026-01-13 | Woods Keith | Chief Operating Officer | Sell | 17K | $42.70 | $715K | 583K |
| 2026-01-13 | Vaishnaw Akshay | President of R&D | Sell | 20K | $42.70 | $873K | 596K |
| 2026-01-13 | Hallal David | Chief Executive Officer | Sell | 57K | $42.70 | $2.5M | 1.5M |
| 2025-12-16 | Peng Katie | n/a | Sell | 280 | $44.63 | $12K | 33K |
| 2025-12-16 | Peng Katie | n/a | Sell | 726 | $43.88 | $32K | 33K |
| 2025-12-12 | AKKARAJU SRINIVAS | n/a | X | 1.1M | $7.35 | $7.8M | 6.4M |
| 2025-12-11 | Invus Global Management, LLC | n/a | X | 1.6M | $7.35 | $11.6M | 10.8M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
Large holders (13D and 13G)
One row per reporting person, newest filing first. JSON8 holders above 5% have filed on SRRK, all on Schedule 13G (passive). The largest reported stake is Siren, L.L.C. at 8.0% of the class (9,575,013 shares), filed 2026-08-13 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-14 | 13G/Ano. 11 | Redmile Group, LLCinvestment adviser, other entity | 4.3M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 11 | Jeremy C. Greenparent holding company, individual | 4.3M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 11 | RedCo II Master Fund, L.P.partnership, non-US institution | 0 | 0.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Siren, L.L.C.other entity | 9.6M | 8.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Invus Public Equities, L.P.partnership | 9.6M | 8.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Raymond Debbaneindividual | 9.6M | 8.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Invus Public Equities Advisors, LLCother entity | 9.6M | 8.0% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 10 | Invus Global Management, LLCother entity | 9.6M | 8.0% | 2026-06-30 |
13F holders
Tracked managers holding SRRK at their latest 13F. JSON8 of the 30 tracked managers held SRRK at their latest 13F, $83.9M in total at quarter-end prices. Citadel Advisors is the largest at $25.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 460K | $25.3M | 0.00% | -527K |
| Fisher Asset Management | 2026-06-30 | 439K | $24.2M | 0.01% | -19K |
| AQR Capital Management | 2026-06-30 | 248K | $13.6M | 0.00% | +36K |
| D. E. Shaw & Co. | 2026-06-30 | 245K | $13.5M | 0.01% | +230K |
| Renaissance Technologies | 2026-06-30 | 92K | $5.0M | 0.01% | -200K |
| Millennium Management | 2026-06-30 | 18K | $994K | 0.00% | new or n/a |
| Point72 Asset Management | 2026-06-30 | 15K | $836K | 0.00% | 0 |
| Two Sigma Investments | 2026-06-30 | 10K | $525K | 0.00% | -169K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$300.0M of operating cash flow. As of 2026-06-30, cash was $437.1M against $196.2M of debt.
- Cash
- $437.1M
- Debt
- $196.2M
- Equity
- $253.8M
- Total assets
- $523.5M
- Shares outstanding
- 121,785,282
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | n/a | -$109.9M | n/a | -0.84 |
| Q1 2026 | 2026-03-31 | $0 | -$105.5M | n/a | -0.83 |
| Q4 2025derived | 2025-12-31 | n/a | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | n/a | -$102.2M | n/a | -0.90 |
| Q2 2025 | 2025-06-30 | n/a | -$110.0M | n/a | -0.98 |
| Q1 2025 | 2025-03-31 | n/a | -$74.7M | n/a | -0.67 |
| Q3 2024 | 2024-09-30 | n/a | -$64.5M | n/a | -0.66 |
| Q2 2024 | 2024-06-30 | n/a | -$58.5M | n/a | -0.60 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | n/a | -$300.0M | $602K | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | n/a | -$200.9M | $98K | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | n/a | -$145.2M | $71K | n/a | n/a |
| FY 2022 | 2022-12-31 | $33.2M | -$134.5M | -$132.7M | $1.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | $18.8M | -$131.8M | -$126.8M | $5.2M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-08-03 from the cover page.
What this page is
Scholar Rock Holding Corp in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows Scholar Rock Holding Corp (SRRK), SEC CIK 1727196, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GEDGAR read every 30 minutes; 13D within five business days of crossing 5%, 13G on the passive schedule. Latest 2026-08-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-06-04.JSON and CSV
- Company record
- EDGAR filing index for CIK 1727196Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as biological products, (no diagnostic substances)
- KYMRKymera Therapeutics, Inc.
- ADPTAdaptive Biotechnologies Corp
- TWSTTwist Bioscience Corp
- HALOHALOZYME THERAPEUTICS, INC.
- KRYSKrystal Biotech, Inc.
- NBIXNEUROCRINE BIOSCIENCES INC
- RVMDRevolution Medicines, Inc.
- AMGNAMGEN INC
- MAZEMaze Therapeutics, Inc.
- GILDGILEAD SCIENCES, INC.
- RXRXRECURSION PHARMACEUTICALS, INC.
- APGEApogee Therapeutics, Inc.
- FENCFENNEC PHARMACEUTICALS INC.
- PCVXVaxcyte, Inc.
- BIIBBIOGEN INC.
- VORVor Biopharma Inc.
- EXELEXELIXIS, INC.
- ADMAADMA BIOLOGICS, INC.
- VCELVericel Corp
- TECHBIO-TECHNE Corp
- ARTVArtiva Biotherapeutics, Inc.
- BCRXBIOCRYST PHARMACEUTICALS INC
- VIRVir Biotechnology, Inc.
- IOVAIOVANCE BIOTHERAPEUTICS, INC.
Datasets
Frequently Asked Questions
How much of SRRK is sold short?
What is SRRK's daily short volume?
Does SRRK have fails to deliver?
Are SRRK insiders buying or selling?
Who owns more than 5% of SRRK?
What did SRRK report last quarter?
Which funds hold SRRK?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.